Pulocimab
- Generic Name
- Pulocimab
Akeso's Bispecific Antibodies Show Promise in Lung and Colorectal Cancers
• Akeso's ivonescimab, a PD-1/VEGF bispecific antibody, gains approval in China for EGFR-mutated NSCLC and shows significant benefits in PD-L1 positive NSCLC compared to pembrolizumab.
• Ligufalimab, a CD47 monoclonal antibody, enters Phase III trials for head and neck squamous cell carcinoma, marking the first CD47 mAb in Phase III for solid tumors.
• Ivonescimab, combined with FOLFOXIRI, demonstrates high anti-tumor activity in first-line treatment of MSS/pMMR metastatic colorectal cancer, with a 88.2% objective response rate.
• Akeso is advancing a diverse pipeline of innovative therapies, including bispecific antibodies and ADCs, with multiple Phase III trials underway across various cancer types.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath